The study, published July 30 in Proceedings of the National Academy of Sciences (PNAS) , also points to a breakthrough new class of anti-depressant that is faster-acting and free of side effects than the current treatments that have been in use for the past 30 years
Tirzepatide is a dual GIP and GLP-1 receptor agonist, the first of its kind to target two metabolic pathways simultaneously
None of the patients recruited in the final cohort were prescribed either cyanide, carbamazepine, valproic acid or iron, which can cause secondary hyperammonemia as a result of disruption of mitochondrial pathways (17,18)
At the moment, the only legal way to access retatrutide is through an authorised clinical trial
Abbreviations AC, Adenylyl cyclase
Time-Saving: Skip the manual math and let our calculator handle the work for you